PALLIATIVE RADIATION DURING PEMETREXED PLUS CISPLATIN FIRST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PATIENT SAFETY IN THE JMDB AND PARAMOUNT TRIALS

被引：0
|
作者：
Scagliotti, G. V. [1 ]
Gridelli, C. [2 ]
de Marinis, F. [3 ]
Biesma, B. [4 ]
Reck, M. [5 ]
San Antonio, B. [6 ]
Zimmermann, A. H. [7 ]
Visseren-Grul, C. [8 ]
Chouaki, N. [9 ]
Paz-Ares, L. [10 ]
机构：
[1] Univ Turin, Turin, Italy
[2] San Giuseppe Moscati Hosp, Dept Oncol Hematol, Avellino, Italy
[3] San Camillo Forlanini Hosp, Oncol Pulm Unit 1, Rome, Italy
[4] Jeroen Bosch Hosp, Dept Pulm Dis, sHertogenbosch, Netherlands
[5] Hosp Grosshansdorf, Grosshansdorf, Germany
[6] Eli Lilly & Co, Oncol, Madrid, Spain
[7] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA
[8] Eli Lilly & Co, Oncol Thorac, Houten, Netherlands
[9] Eli Lilly & Co, Oncol Thorac, Paris, France
[10] Seville Univ Hosp, Seville, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2014年 / 9卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
113P
引用
收藏
页码：S45 / S45
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, B.
    Chu, T.
    Zhong, R.
    Zhong, H.
    Zhang, B.
    Zhang, W.
    Shi, C.
    Qian, J.
    Han, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S129 - S129
  • [32] PEMETREXED AND CARBOPLATIN VERSUS DOCETAXEL AND CARBOPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC)
    Ganju, Vinod
    Pereira, Jose
    Kim, Joo-Hang
    Magallanes, Manuel
    Lee, Dae-Ho
    Wang, Jie
    Martinez, Luis
    Barraclough, Helen
    Van Kooten, Maximiliano
    Orlando, Mauro
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S417 - S418
  • [33] The importance of histology when evaluating the cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced non-small cell lung cancer
    Muehlenbein, C. E.
    Klein, R. W.
    Liepa, A. M.
    Babineaux, S. M.
    Wielage, R. C.
    Schwartzberg, L. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] Efficacy and tolerability of a weekly schedule of docetaxel-cisplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC)
    Binder, D.
    Hackenthal, M.
    Graseck, L.
    Schweisfurth, H.
    Schaeper, C.
    Kruell, M.
    Temmesfeld-Wollbrueck, B.
    Suttorp, N.
    Beinert, T.
    Hellriegel, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Bevacizumab as first-line treatment for advanced non-small cell lung cancer
    Socinski, Mark A.
    DRUGS OF TODAY, 2008, 44 (04) : 293 - 301
  • [36] Docetaxel (Taxotere®) as first-line therapy of advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    ONKOLOGIE, 2003, 26 : 26 - 32
  • [37] Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer
    Farhat, Fadi S.
    Ghosn, Marwan G.
    Kattan, Joseph G.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (02) : 235 - 242
  • [38] Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer
    Fadi S. Farhat
    Marwan G. Ghosn
    Joseph G. Kattan
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 235 - 242
  • [39] ORAL VINORELBINE PLUS CISPLATIN VERSUS PEMETREXED PLUS CISPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER: A COST MINIMIZATION ANALYSIS IN TWELVE EUROPEAN COUNTRIES
    Bucher, D.
    Grossi, F.
    VALUE IN HEALTH, 2015, 18 (07) : A446 - A446
  • [40] Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial
    Gervais, Radj
    Robinet, Gilles
    Clement-Duchene, Christelle
    Denis, Fabrice
    El Kouri, Claude
    Martin, Philippe
    Chouaki, Nadia
    Bourayou, Nawel
    Morere, Jean-Francois
    LUNG CANCER, 2013, 80 (02) : 185 - 190
12345